C4X Discovery Holdings PLC Result of AGM (6203V)
01 February 2017 - 12:06AM
UK Regulatory
TIDMC4XD
RNS Number : 6203V
C4X Discovery Holdings PLC
31 January 2017
C4X Discovery Holdings plc
("C4XD" or the "Company")
Result of AGM
31 January, 2017 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that at its Annual
General Meeting held today at 12:00 noon at The Podium, Euston, 1
Eversholt Street, London NW1 1AD, all resolutions were duly
passed.
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Zeus Capital Limited
Dan Bate 0161 831 1512
Dominic Wilson/Phil Walker 0203 829 5000
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4X's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction,
diabetes and inflammation with a number of new drug candidates
identified and further progress made towards the clinic. In
selecting new targets C4X Discovery will focus on the high-value
disease areas of inflammation and neurodegeneration, and will
continue to maximise value from opportunistic areas, for example,
immuno-oncology.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4X to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGBXGDBUGXBGRB
(END) Dow Jones Newswires
January 31, 2017 08:06 ET (13:06 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024